Skip to content

Treatment of Central Obesity with Unani Medicine Jawarish-e-Bisbasa.

Clinical Validation of Unani Pharmacopoeal formulation Jawarish-e-Bisbasa in cases of Saman e Mufrit (Central Obesity)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015404
Enrollment
240
Registered
2018-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E668- Other obesity Health Condition 2: null- Saman e Mufrit (Central Obesity)

Interventions

Intervention1: Jawarish-e-Bisbasa: Jawarish-e-Bisbasa Semi solid Oral 7gm twice Daily take after meals with Luke warm water for 8 weeks Control Intervention1: Nil: Nil

Sponsors

Central Council for Research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Saman Mufrit (Central Obesity) presenting with the following: 1 BMI Male equal to or less than 34.99 kg/m2 and Female equal to or less than 32.49 kg/m2) 2 Waist Circumference (more than 94cms in Males and more than 80 cms in Females) 3 Waist â?? to â?? hip ratio between (more than 80cm to less than 1m), (Female 80 to 85 and male more than 90cm to less than 1m) 4 Saggital Abdominal Diameter (SAD) more than 25 cms 5 Patients presenting with central obesity with or without following complaints: I. Heart burn II. Fullness of stomach III. Breathing difficulties IV. Sleep apnea

Exclusion criteria

Exclusion criteria: 1. Medications causing secondary weight gain e.g.Phenothiazines, sodium valproate, carbamazepine, lithium, glucocorticoids, thiazolidinedioneâ??s, sulphonylureas, adrenergic antagonists, etc 2. Patient on Oral contraceptive pills or Hormone Replacement therapy 3. Patient having systemic illness requiring long term treatment 4. Patients unable to exercise 5. Pregnant and lactating females

Design outcomes

Primary

MeasureTime frame
Improvement in sign and symptoms of Saman e Mufrit (Central Obesity)Timepoint: 8 weeks

Secondary

MeasureTime frame
Hematological and biochemical assessments for safetyTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026